Back to Journals » Therapeutics and Clinical Risk Management » Volume 15

Therapeutic Approaches to Gastric Hepatoid Adenocarcinoma: Current Perspectives

Authors Søreide JA

Received 8 October 2019

Accepted for publication 13 December 2019

Published 23 December 2019 Volume 2019:15 Pages 1469—1477


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Garry Walsh

Jon Arne Søreide1,2

1Department of Gastrointestinal Surgery, Stavanger University Hospital, Stavanger, Norway; 2Department of Clinical Medicine, University of Bergen, Bergen, Norway

Correspondence: Jon Arne Søreide
Department of Gastrointestinal Surgery, Stavanger University Hospital, POB 8100, Stavanger N-4022, Norway
Tel +47 905 31770
Fax +47 51519919

Abstract: Hepatoid adenocarcinoma of the stomach (HAS) is a rare subgroup of gastric cancer (GC). Morphologically, this tumor exhibits both adenocarcinomatous and hepatocellular differentiation, and most tumors show immunohistochemical staining for alpha-fetoprotein (AFP) or elevated AFP serum levels. The diagnosis of HAS is frequently delayed, and at least half of patients have advanced disease at the time of diagnosis. Despite a lack of evidence, treatment approaches have mostly followed principles for the treatment of common gastric cancer (CGC), including radical surgery in eligible patients with curative intent. The indications for and the type of adjuvant systemic treatments remain unclear. Additionally, there is a lack of evidence allowing any firm conclusions to be drawn regarding the best treatment for patients with metastatic HAS (mHAS). Chemotherapy regimens, including cisplatin-based chemotherapy, are considered the most efficient first-line systemic treatment in advanced situations. Their combination with targeted therapy (i.e., trastuzumab) in HER2-positive tumors seems promising. The rarity of these patients and the scarce and heterogeneous literature on this particular subgroup of GC make it difficult to provide any robust evidence for the clinical management of patients with HAS.

Keywords: hepatoid adenocarcinoma, stomach, gastric, alpha-fetoprotein, therapy, prognosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]